Page 1

Exhibit 99.1 Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update Planned IND submission for SZN - 8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN - 8141 Phase 1b / 2a study , DUET , by year - end 2026 with initial data anticipated in the second half of 2027 U.S. Patent Trial and Appeal Board denies institution of post - grant review petition challenging Surrozen patent SOUTH SAN FRANCISCO , Calif . , August 6 , 2026 ( GLOBE NEWSWIRE ) -- Surrozen , Inc. ( “ Surrozen ” or the “ Company ” ) ( Nasdaq : SRZN ) , a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight - threatening ophthalmic conditions , today announced financial results for the second quarter ended June 30 , 2026 and provided a business update . " We continue to execute our strategy of building a leading ophthalmology franchise centered on the therapeutic potential of Wnt biology , " said Craig Parker , Chief Executive Officer of Surrozen . " The planned DUET Phase 1b / 2a study represents an important step in the clinical development of SZN - 8141 and reflects our commitment to generate meaningful evidence to guide future development across retinal vascular disease . In addition , the recent U.S. Patent Trial and Appeal Board ( PTAB ) decision denying the institution of Merck's post - grant review petition reinforces our intellectual property position . Together , these advancements further strengthen the foundation of our ophthalmology franchise and support our long - term growth strategy . " Business Highlights , Recent Developments and Upcoming Milestones o The Company continues to advance its ophthalmology pipeline ( SZN - 8141 and SZN - 8143 ) and expects to submit an Investigational New Drug ( IND ) application for SZN - 8141 by the end of the third quarter of 2026 and initiate the DUET Phase 1b / 2a study in diabetic macular edema ( DME ) patients by year - end 2026